about
Incidence of Tuberculosis among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy in Europe and North AmericaTiming of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studiesFeasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study)Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral TherapyLong-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical PracticePredicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.The need for data on women living with HIV in Europe.Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA).Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis C coinfection: data from the ICONA foundation cohort.Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: data from the ICONA foundation study group, years 1997-2013.Increased incidence of sexually transmitted diseases in the recent years: data from the ICONA cohort.Increased risk of virological failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort.Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study CohortAn updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study.Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study.Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation CohortHigh-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects: Data from the ICONA Foundation Cohort.Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D) study.Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study).Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study.Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort.Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC).The Human Immunodeficiency Virus Continuum of Care in European Union Countries in 2013: Data and Challenges.Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitorsIncreased bone marrow interleukin-7 (IL-7)/IL-7R levels but reduced IL-7 responsiveness in HIV-positive patients lacking CD4+ gain on antiviral therapyImpact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patientsEvidence for polymicrobic flora translocating in peripheral blood of HIV-infected patients with poor immune response to antiretroviral therapy.High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations.Predictors of having a resistance test following confirmed virological failure of combination antiretroviral therapy: data from EuroSIDA.Survival outcomes and effect of early vs. deferred cART among HIV-infected patients diagnosed at the time of an AIDS-defining event: a cohort analysisPrognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: a multilevel analysis.Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patientsT-cell phenotypes, apoptosis and inflammation in HIV+ patients on virologically effective cART with early atherosclerosisGender differences in HIV-positive persons in use of cardiovascular disease-related interventions: D:A:D studyCD4 cell count and the risk of infective and non-infective serious non-AIDS events in HIV-positive persons seen for care in Italy.
P50
Q21521430-936EAF5B-114C-427F-A384-E7F3F1AD3520Q24656950-15917A28-15B5-42D9-88B2-64358ED64558Q28485122-B59A3C62-5D8D-4509-A25C-5AF7D9047D2AQ28534394-193FE240-C1DA-434C-8EF2-872A581E7970Q28553516-C634B44A-38BF-4AF1-8651-047F6DBB5723Q28554567-45882BFC-05A5-4E1B-8891-04138E1238E8Q30573969-8E3136A3-A56D-489C-8E5D-A63D40C05CC9Q30650427-FD3C7B6D-841C-4F00-8DC4-9B386E0260AEQ30787775-5862816A-8124-4D3E-AAB4-4298A2013C9DQ30843946-75EE6BF9-4149-40BF-8FB6-57E03C82B8D8Q30860210-571EFDCC-9947-4E9C-8B97-7E160687876CQ30869471-F6A9349E-C071-4F17-94C9-0DAEB0C3ABC0Q30869845-EF7D9524-ED14-4499-AD80-820CD9BB589BQ30869874-C1BB02E2-94BF-4798-87ED-D9BE94625390Q30934548-64292E55-D6E1-4D12-B15A-E8358B1E6D9DQ31050092-24EEDBE1-6B8C-4C2C-8619-36B0C4B63BF4Q31110946-1E8A9F2E-C010-470D-BDDA-6A8FB02BFAE4Q31127155-849184A8-13B5-4BC9-9DF3-CF45A7BA33A9Q31146395-0F08CAF8-E8B9-4707-B642-44049A86DBD5Q33389734-2537FF62-1A22-4AD6-AAFF-6EA1F7FA6575Q33404972-E2CEE36D-3F46-49C5-93B5-CE7F08BDAF85Q33521080-B2835A7A-57DA-44A0-960C-9B2B71A77075Q33602915-A6269F3B-53D6-455C-BD54-ED45ED90B44DQ33699364-54B85B04-FB1C-4670-9789-50B019DDAC80Q33703634-1B6FB77B-34BA-4EF6-AE2C-2BF9B94F8562Q33736040-2A81394C-BE94-4E23-B3DF-839979E25ADAQ33737070-FD0C90A2-412E-47F0-9DF6-3A945A416A5CQ33770040-93B0FC6E-49B6-4444-8EEC-08D44A12B0D9Q33786846-53CD4F95-29CA-4B98-B8B5-7AC38FBC1E22Q33816061-A9AD8300-7BA1-4A26-AE14-544C9113C884Q33873507-94E603D6-A4D3-41FE-8032-5C29F865699AQ33911980-9A6C26BC-8A15-4632-A07C-532A5FC53A15Q33982469-C11E9E19-95C8-4A7B-9910-D588DB1D9CB6Q34063630-62EAC9A4-2DB1-432A-9D78-C690611325C7Q34139859-6E59DA7A-E873-47CC-8C4D-8ACDCF5720D4Q34159738-972E14C3-DDCF-4DDE-8AC4-297287EE3E51Q34171589-FA2AD736-D9CC-4D87-9060-47E7048217D2Q34430776-AFE60FB2-8CCB-4D5C-A4F8-0A1A79475FCDQ34474941-11724CBE-CD65-47A6-9ED8-1F9927ADCF3BQ34475027-E017CF1A-55CA-47EB-83D5-5A718FF47046
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Antonella d'Arminio Monforte
@ast
Antonella d'Arminio Monforte
@en
Antonella d'Arminio Monforte
@es
Antonella d'Arminio Monforte
@nl
type
label
Antonella d'Arminio Monforte
@ast
Antonella d'Arminio Monforte
@en
Antonella d'Arminio Monforte
@es
Antonella d'Arminio Monforte
@nl
altLabel
Antonella D'Arminio Monforte
@en
prefLabel
Antonella d'Arminio Monforte
@ast
Antonella d'Arminio Monforte
@en
Antonella d'Arminio Monforte
@es
Antonella d'Arminio Monforte
@nl
P106
P21
P31
P496
0000-0003-0073-1789